ACE Inhibitor-induced angioedema

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalCurrent Allergy and Asthma Reports
Volume12
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Hereditary Angioedemas
Angioedema
Angiotensin-Converting Enzyme Inhibitors
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

@article{ee0ae0684b5046eeb88bf45f8e8a440f,
title = "ACE Inhibitor-induced angioedema",
abstract = "Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.",
author = "Monali Vasekar and Timothy Craig",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s11882-011-0238-z",
language = "English (US)",
volume = "12",
pages = "72--78",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "1",

}

ACE Inhibitor-induced angioedema. / Vasekar, Monali; Craig, Timothy.

In: Current Allergy and Asthma Reports, Vol. 12, No. 1, 01.02.2012, p. 72-78.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ACE Inhibitor-induced angioedema

AU - Vasekar, Monali

AU - Craig, Timothy

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

AB - Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

UR - http://www.scopus.com/inward/record.url?scp=84857627080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857627080&partnerID=8YFLogxK

U2 - 10.1007/s11882-011-0238-z

DO - 10.1007/s11882-011-0238-z

M3 - Article

VL - 12

SP - 72

EP - 78

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 1

ER -